<DOC>
	<DOCNO>NCT02460679</DOCNO>
	<brief_summary>Open label study EPI-589 ALS subject</brief_summary>
	<brief_title>Safety Biomarker Study EPI-589 Subjects With ALS</brief_title>
	<detailed_description>Open label 30-day run phase establish baseline parameter 90-day withdrawal phase determine duration treatment response .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Dx . ALS E1 Escorial Criteria FVC &gt; = 70 % year age Weakness onset within 3 year Agreement use contraception age appropriate Willingness ability comply study procedure Stable regimen dietary supplement /or riluzole least 30 day prior study Absention use investigative nonapproved drug Subject must able swallow size 0 tablet Allergy EPI589 Use ventilation Participation intervention study Inability undergo MRI MRS Dx neurologic disease Malignancy within past 2 year Hx . stroke Hx . brain injury Hepatic insufficiency ( LFTs &gt; 3 x ULN ) Renal insufficiency require dialysis End stage cardiac failure Participation trial device , drug tx . ALS within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>